Abstract
The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment- related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.
| Original language | English |
|---|---|
| Pages (from-to) | 1579-1582 |
| Number of pages | 4 |
| Journal | Archives of Internal Medicine |
| Volume | 160 |
| Issue number | 11 |
| State | Published - Jun 12 2000 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
Cite this
Update on antiplatelet therapy for stroke prevention. / Sacco, Ralph L; Elkind, Mitchell S.
In: Archives of Internal Medicine, Vol. 160, No. 11, 12.06.2000, p. 1579-1582.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Update on antiplatelet therapy for stroke prevention
AU - Sacco, Ralph L
AU - Elkind, Mitchell S.
PY - 2000/6/12
Y1 - 2000/6/12
N2 - The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment- related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.
AB - The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment- related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.
UR - http://www.scopus.com/inward/record.url?scp=0034640939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034640939&partnerID=8YFLogxK
M3 - Article
C2 - 10847250
AN - SCOPUS:0034640939
VL - 160
SP - 1579
EP - 1582
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
SN - 2168-6106
IS - 11
ER -